Dianthus Therapeutics (NASDAQ:DNTH) Stock: Insider Ryan Savitz Sells 17,724 Shares

Key Points

• EVP Ryan Savitz sold 17,724 Dianthus Therapeutics shares at an average $90.56, totaling about $1.61 million. He retained 29,276 shares; the sale reduced his direct ownership by 37.71%.
• Savitz also reported several recent sales, including 100,713 shares on November 9 for about $9.12 million.
• Dianthus shares traded at $92.48, while analysts’ consensus rating was Buy with an average price target of $128.77. The company’s latest quarterly loss per share was narrower than expected, and revenue exceeded estimates.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 17,724 shares of Dianthus Therapeutics stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $90.56, for a total transaction of $1,605,085.44. Following the transaction, the executive vice president directly owned 29,276 shares of the company's stock, valued at approximately $2,651,234.56. This trade represents a 37.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Ryan Savitz also recently made the following trade(s):

• On Wednesday, November 11th, Ryan Savitz sold 3,044 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $90.03, for a total transaction of $274,051.32.
• On Monday, November 9th, Ryan Savitz sold 100,713 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.54, for a total transaction of $9,118,555.02.
• On Tuesday, November 10th, Ryan Savitz sold 2,561 shares of Dianthus Therapeutics stock. The stock was sold at an average price of $90.14, for a total transaction of $230,848.54.

Dianthus Therapeutics Price Performance

DNTH stock traded up $3.18 during midday trading on Thursday, hitting $92.48. 921,016 shares of the stock traded hands, compared to its average volume of 931,449. The firm has a market cap of $5.21 billion, a P/E ratio of -23.18 and a beta of 1.47. The stock's fifty day simple moving average is $89.05 and its 200-day simple moving average is $86.15. Dianthus Therapeutics, Inc. has a 1-year low of $34.29 and a 1-year high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $0.13. Dianthus Therapeutics had a negative net margin of 7,436.50% and a negative return on equity of 19.68%. The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $0.46 million. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -3.55 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $134.00 price target on shares of Dianthus Therapeutics in a report on Thursday, November 5th. Wedbush increased their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. Citigroup assumed coverage on Dianthus Therapeutics in a report on Friday, September 4th. They issued a "buy" rating and a $156.00 price objective on the stock. HC Wainwright restated a "buy" rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $128.77.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $401,990,000. Wellington Management Group LLP raised its position in shares of Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company's stock worth $314,849,000 after purchasing an additional 634,099 shares during the last quarter. ABS Investment Management LLC acquired a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $194,960,000. Assenagon Asset Management S.A. raised its position in shares of Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company's stock worth $64,474,000 after purchasing an additional 451,597 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Dianthus Therapeutics in the 1st quarter valued at about $40,713,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics is a clinical-stage biotechnology company developing medicines for autoimmune and inflammatory diseases involving the complement system, a part of the immune system. The company's research focuses on selectively targeting complement activity that contributes to disease. Dianthus became a publicly traded company in 2023 through a merger with Magenta Therapeutics. Its clinical development activities are intended to support potential use across patient populations, though the company has not established a commercial geographic footprint.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.